Plus, news about Equillium and Structure Therapeutics:
ArriVent, Alphamab team up on multi-ADC collab: The companies will work together to develop multiple antibody-drug conjugates using Alphamab’s technology. ArriVent gets the right to commercialize any products globally, except in China, Hong Kong, Macau and Taiwan. Upfront and milestone payments can reach up to $615.5 million. — Max Gelman
Annexon plans $125M offering: The startup is putting together the raise after releasing Phase 3 data for its Guillain-Barré syndrome treatment on Tuesday. Annexon aims to file for approval in the first half of next year once a real-world study reads out comparing the pivotal trial results in patients in Bangladesh and the Philippines to Western populations. — Max Gelman
Equillium announces Ph2 data, stock falls: The biotech touted results from an open-label alopecia study in which its drug improved scores on a hair loss scale by 20 points in 5 of 25 patients, regardless of disease severity. In patients with severe disease, only three of 14 responded, and none of the eight individuals with very severe disease responded. Equillium’s stock $EQ closed 27% lower on Tuesday. — Max Gelman
Structure Therapeutics’ offering: The same day that the company shared positive mid-stage weight loss data for its oral GLP-1, it announced it’s selling 8 million shares. — Katherine Lewin